Operating Expenses

Acquired IPR&D Expense

Pfizer Acquired IPR&D Expense increased by 1422.2% to $137.00M in Q1 2026 compared to the prior quarter.

Analysis

StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2025
Last reportedQ1 2026
Metric ID: is_abbv_acquired_iprd_expense

Historical Data

2 periods
 Q1 '25Q1 '26
Value$9.00M$137.00M
QoQ Change—>999%
YoY Change—>999%
Range$9.00M – $137.00M
Avg YoY Growth>999%
Median YoY Growth>999%

Business Segments

View all
SegmentQ1 '26
Biopharma$137.00M
Total$137.00M

Acquired IPR&D Expense at Other Companies

Eli Lilly logo
Eli LillyLLYView metric

Frequently Asked Questions

What is Pfizer's acquired ipr&d expense?
Pfizer (PFE) reported acquired ipr&d expense of $137.00M in Q1 2026.